WO2003034945A1 - Vaisseau artificiel et procede de realisation - Google Patents
Vaisseau artificiel et procede de realisation Download PDFInfo
- Publication number
- WO2003034945A1 WO2003034945A1 PCT/JP2002/010986 JP0210986W WO03034945A1 WO 2003034945 A1 WO2003034945 A1 WO 2003034945A1 JP 0210986 W JP0210986 W JP 0210986W WO 03034945 A1 WO03034945 A1 WO 03034945A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- blood vessel
- artificial blood
- solution
- cell
- porous
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 13
- 239000000463 material Substances 0.000 claims abstract description 98
- 229940088623 biologically active substance Drugs 0.000 claims abstract description 40
- 239000011148 porous material Substances 0.000 claims abstract description 25
- 210000004204 blood vessel Anatomy 0.000 claims description 162
- 239000002473 artificial blood Substances 0.000 claims description 156
- 210000004027 cell Anatomy 0.000 claims description 44
- 239000000499 gel Substances 0.000 claims description 30
- 229920005989 resin Polymers 0.000 claims description 28
- 239000011347 resin Substances 0.000 claims description 28
- 239000000758 substrate Substances 0.000 claims description 28
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 24
- 239000000126 substance Substances 0.000 claims description 23
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 22
- 238000004519 manufacturing process Methods 0.000 claims description 21
- 230000000975 bioactive effect Effects 0.000 claims description 20
- 229920001577 copolymer Polymers 0.000 claims description 19
- 210000002889 endothelial cell Anatomy 0.000 claims description 17
- 239000004310 lactic acid Substances 0.000 claims description 12
- 235000014655 lactic acid Nutrition 0.000 claims description 12
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 9
- 102000008186 Collagen Human genes 0.000 claims description 8
- 108010035532 Collagen Proteins 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 229920001436 collagen Polymers 0.000 claims description 8
- -1 polytetrafluoroethylene Polymers 0.000 claims description 8
- 230000003014 reinforcing effect Effects 0.000 claims description 8
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 7
- 239000004626 polylactic acid Substances 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 5
- 102000009123 Fibrin Human genes 0.000 claims description 5
- 108010073385 Fibrin Proteins 0.000 claims description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 5
- 229920000615 alginic acid Polymers 0.000 claims description 5
- 235000010443 alginic acid Nutrition 0.000 claims description 5
- 238000006911 enzymatic reaction Methods 0.000 claims description 5
- 229950003499 fibrin Drugs 0.000 claims description 5
- 229920013716 polyethylene resin Polymers 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 claims description 4
- 239000005062 Polybutadiene Substances 0.000 claims description 4
- 229920000954 Polyglycolide Polymers 0.000 claims description 4
- WHBMMWSBFZVSSR-UHFFFAOYSA-N R3HBA Natural products CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims description 4
- 210000002950 fibroblast Anatomy 0.000 claims description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 4
- 210000003494 hepatocyte Anatomy 0.000 claims description 4
- 229920002492 poly(sulfone) Polymers 0.000 claims description 4
- 229920000070 poly-3-hydroxybutyrate Polymers 0.000 claims description 4
- 229920002857 polybutadiene Polymers 0.000 claims description 4
- 239000004633 polyglycolic acid Substances 0.000 claims description 4
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 4
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 claims description 3
- 229920000936 Agarose Polymers 0.000 claims description 3
- 239000004743 Polypropylene Substances 0.000 claims description 3
- 239000000783 alginic acid Substances 0.000 claims description 3
- 229960001126 alginic acid Drugs 0.000 claims description 3
- 150000004781 alginic acids Chemical class 0.000 claims description 3
- 210000003127 knee Anatomy 0.000 claims description 3
- 229920002791 poly-4-hydroxybutyrate Polymers 0.000 claims description 3
- 229920001155 polypropylene Polymers 0.000 claims description 3
- 229920005990 polystyrene resin Polymers 0.000 claims description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- 239000004925 Acrylic resin Substances 0.000 claims description 2
- 239000011543 agarose gel Substances 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 239000000512 collagen gel Substances 0.000 claims description 2
- MIZLGWKEZAPEFJ-UHFFFAOYSA-N 1,1,2-trifluoroethene Chemical group FC=C(F)F MIZLGWKEZAPEFJ-UHFFFAOYSA-N 0.000 claims 1
- 239000004793 Polystyrene Substances 0.000 claims 1
- 229920005678 polyethylene based resin Polymers 0.000 claims 1
- 229920005673 polypropylene based resin Polymers 0.000 claims 1
- 229920002223 polystyrene Polymers 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 9
- 230000002785 anti-thrombosis Effects 0.000 abstract description 7
- 230000002349 favourable effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 56
- 230000000052 comparative effect Effects 0.000 description 12
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 10
- 229920001432 poly(L-lactide) Polymers 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000011282 treatment Methods 0.000 description 7
- 230000002792 vascular Effects 0.000 description 7
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 7
- 239000013543 active substance Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 208000019553 vascular disease Diseases 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 4
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 239000001099 ammonium carbonate Substances 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 206010007269 Carcinogenicity Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010064390 Tumour invasion Diseases 0.000 description 2
- 206010047163 Vasospasm Diseases 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 229940019700 blood coagulation factors Drugs 0.000 description 2
- 230000009400 cancer invasion Effects 0.000 description 2
- 230000007670 carcinogenicity Effects 0.000 description 2
- 231100000260 carcinogenicity Toxicity 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 2
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 101100290380 Caenorhabditis elegans cel-1 gene Proteins 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 201000009628 adenosine deaminase deficiency Diseases 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000389 anti-prion effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000009751 slip forming Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/64—Animal cells
Definitions
- the present invention relates to a vascular prosthesis for use in the treatment of various vascular diseases of the human body, including heart and brain diseases, and peripheral blood vessels of the extremities, and more particularly, to a porous vascular prosthesis substrate and gel.
- the present invention relates to an artificial blood vessel in which a living body and a bioactive substance are combined.
- Artificial blood vessels with large diameters are used in the treatment of vascular diseases such as congenital diseases and arteriosclerosis.
- vascular diseases such as congenital diseases and arteriosclerosis.
- human blood vessels made of materials such as polyester fibers and extensible fluorine tetrachloride compounds are used clinically.
- Large-diameter artificial blood vessels have achieved sufficient clinical results because they have a sufficient blood flow velocity even if made of such materials.
- Artificial blood vessels of small diameter are used for the treatment of vascular diseases such as arteriosclerosis, vasospasm, damage to peripheral blood vessels, aneurysm formation, and tumor invasion. Demand is very high.
- vascular diseases such as arteriosclerosis, vasospasm, damage to peripheral blood vessels, aneurysm formation, and tumor invasion.
- Demand is very high.
- the above-mentioned materials are non-biodegradable materials, have poor biocompatibility, and have a problem that foreign matter remains in the body even after forceful implantation.
- a culture solution containing smooth muscle cells is directly inoculated into a biodegradable or non-biodegradable tubular structure, whereby the endothelial cells are cultured until the lumen surface is smoothed.
- a model for seeding has also been proposed (Niklason et al. Science, 1999, 284, p489-493, JP-A-2001-78750). According to these models, they have excellent mechanical strength and can withstand arterial vascular prostheses.
- a biodegradable or non-biodegradable tubular structure has a strong hydrophobicity and remarkably poor cell adhesion and proliferation.
- an artificial blood vessel which is excellent in biocompatibility, mechanical strength, antithrombotic property, etc., does not leak blood, and is easy to manufacture is desired.
- a cylindrical porous artificial blood vessel base material formed of a fiber-like or sponge-like material having an appropriate mechanical strength is converted into a cell-mixed solution. After impregnating under normal pressure or negative pressure conditions, allowing the cell-containing solution to be taken into the pores, and then gelling the solution, the cells can be densified in a short period of time to the fine details of the porous artificial blood vessel substrate.
- a cell-mixed solution After impregnating under normal pressure or negative pressure conditions, allowing the cell-containing solution to be taken into the pores, and then gelling the solution, the cells can be densified in a short period of time to the fine details of the porous artificial blood vessel substrate.
- the present inventors have found that not only cells but also bioactive substances synthesized in vivo, genes encoding those bioactive substances, and pharmaceuticals synthesized or obtained in vitro can be obtained by the same method as described above.
- Pharmaceutical active ingredients such as E.C. compounds can be incorporated into porous artificial blood vessel substrates, and can be used as artificial blood vessels for various uses, including drug delivery systems and artificial organs other than artificial blood vessels. And found that the present invention was completed.
- an artificial blood vessel having a tubular porous artificial blood vessel base material, wherein the pores of the porous artificial blood vessel base material are impregnated with a gel solution containing a biologically active substance.
- the method corresponds to any one of a temperature change, a pH change, a salt concentration change, and an enzyme reaction change.
- Preparing a biologically active substance-containing solution by impregnating the biologically active substance with the solution to be gelled; and preparing the biologically active substance-containing solution in the pores of the porous artificial vascular base under normal pressure or negative pressure conditions. And a step of gelling the bioactive substance-containing solution taken into the pores of the porous artificial blood vessel base material.
- the porous artificial blood vessel substrate is composed of a biodegradable material or a non-biodegradable material.
- the biodegradable material include polylactic acid, polyglycolic acid, copolymers of lactic acid and glycolic acid, polymalic acid, poly one ⁇ - force caprolactone, epsilon - copolymers of force caprolactone and lactic acid, ⁇ -Co-prolatatatone and glycolic acid, ⁇ - Co-polymer of lactic prolactatone, lactic acid and dalicholic acid, poly-3-hydroxybutyrate, poly_4-hydroxybutyrate, and ⁇ 3-hydroxybutyrate It is preferably at least one material selected from the group consisting of a copolymer of methacrylate and 4-hydroxybutylate.
- the non-biodegradable material includes polyethylene resin, polypropylene resin, polybutadiene resin, polystyrene resin, polychlorinated vinyl resin, polyacrylic resin, polymethacrylic resin, and polysulfone resin. And at least one material selected from the group consisting of polytetrafluoroethylene resins.
- the biologically active substance is preferably a cell and Z or a pharmaceutically active ingredient.
- the cells are preferably one or more cells selected from the group consisting of smooth muscle cells, fibroblasts, undifferentiated cells, hepatocytes, knee cells, and hematopoietic stem cells.
- the bioactive substance-containing gel solution is at least one selected from the group consisting of a collagen gel solution, a fibrin gel solution, an acrylamide gel solution, an agarose gel solution, and an alginate gel solution. It is preferable that the gel solution contains a bioactive substance.
- the solution to be gelled may be at least one solution selected from the group consisting of a collagen solution, a fibrin solution, an acrylamide solution, an agarose solution, and an alginic acid solution. preferable.
- an endothelial cell layer may be formed on a lumen surface of the porous artificial blood vessel base material.
- the porous artificial blood vessel base material may be formed by gelling the biologically active substance-containing solution taken into the pores of the porous artificial blood vessel base material.
- the method may further include the step of forming an endothelial cell layer.
- the porous artificial blood vessel base material may be strengthened by a reinforcing member made of a biodegradable material or a non-biodegradable material.
- FIG. 1 is a scanning electron microscope observation image of the inner cavity surface of the artificial blood vessel prepared in Example 1.
- FIG. 2 is a scanning electron microscope observation image of the inner cavity surface of the artificial blood vessel prepared in Comparative Example 1.
- FIG. 3 is a scanning electron microscope observation image of the lumen surface of the PLLA substrate prepared in Reference Example.
- FIG. 4 is a cross-sectional image of the artificial blood vessel prepared in Example 1 by a fluorescence microscope.
- FIG. 5 is a cross-sectional image of the artificial blood vessel prepared in Comparative Example 1 by a fluorescence microscope.
- FIG. 6 is a cross-sectional image of the artificial blood vessel prepared in Example 2 observed by a transmission microscope.
- FIG. 7 is a fluorescent microscope cross-sectional image of the artificial blood vessel prepared in Example 2.
- the artificial blood vessel according to the present invention has a cylindrical porous artificial blood vessel base material, and contains a bioactive substance-containing gel solution in its pores.
- the porous artificial blood vessel base material used in the present invention is porous and preferably has an open pore structure in which the pores are connected from the viewpoint of facilitating the incorporation of a bioactive substance into the pores.
- the percentage of pores is preferably from 70% to 99% of the base material, and more preferably from 80% to 95%.
- the porous artificial blood vessel substrate used in the present invention has a cylindrical shape.
- the inner diameter is preferably 1 mm to 7 mm, and 1 mm to 5 mm. More preferably, it is still more preferably 1 mm to 4 mm.
- the inner diameter is preferably from 5 mm to 70 mm, more preferably from 5 mm to 50 mm.
- Examples of the material of the porous artificial blood vessel base material used in the present invention include a biodegradable material and a non-biodegradable material.
- a biodegradable material is preferable from the viewpoint of providing an artificial blood vessel in which components that are not derived from the living body are not dissolved after transplantation in consideration of foreign body reaction, immune reaction, and carcinogenicity in the living body.
- non-biodegradable materials are preferred from the viewpoint of maintaining mechanical strength because they do not dissolve after transplantation, and providing stable products at the current stage and at the current technological development level. . 02 10986
- the biodegradable material is not particularly limited, but includes polydalicholic acid, polylactic acid, a copolymer of lactate and glycolic acid, polymalic acid, poly-coprolataton, and ⁇ coprolataton and lactic acid.
- Polymers, copolymers of e-proprotatanone and glyco- / reic acid, copolymers of ⁇ -proprotatanone, lactic acid and glycolic acid, poly-3-hydroxybutyrate, poly-1-hydroxybutyrate, Copolymers of 3-hydroxybutyrate and 4-hydroxybutyrate can be mentioned. From the viewpoint of the approval of the Ministry of Health, Labor and Welfare and the FDA (United States Drug Administration), polylactic acid, polyglycolic acid, and lactic acid And a copolymer of glycolic acid and glycolic acid.
- the non-biodegradable material is not particularly limited, but is a polyethylene resin, a polypropylene resin, a polybutadiene resin, a polystyrene resin, a polyvinyl chloride resin, a polyacryl resin, a polymethacryl resin, a polysulfone resin. And polytetrafluoroethylene-based resin. From the viewpoint of approval by the Ministry of Health, Labor and Welfare and the FDA, polyethylene resin and polytetrafluoroethylene-based resin are preferable.
- a foaming agent such as sodium chloride, ammonium hydrogencarbonate, or the like is mixed with a solution of the above-described material and molded into a tubular shape.
- a method of foaming to make it porous can be mentioned.
- Such a method includes, for example, the method described in Nam et al. J. Biomed. Master Res. 2000, 53, pi-7.
- bioactive substance-containing gel solution contained in the pores of the porous artificial blood vessel substrate will be described.
- the gel solution containing a biologically active substance used in the present invention is a gel solution containing a biologically active substance, and it is preferable that the biologically active substance is uniformly mixed.
- Examples of the biologically active substance contained in the gel solution include cells, pharmaceutically active ingredients, and the like, and one or more of these may be used. Such a biologically active substance can be appropriately determined according to the use of the artificial blood vessel.
- a pharmaceutically active ingredient refers to a component that exhibits one or more pharmacological activities in a living body, such as a physiologically active substance synthesized in a living body, and a physiologically active substance thereof.
- Cells used as biologically active substances include, for example, undivided cells such as stem cells and ES cells, smooth muscle cells, fibroblasts, hepatocytes, victory cells, and hematopoietic stem cells. it can.
- physiologically active substance used as a biologically active substance examples include proteins synthesized in vivo, such as insulin, anti-prion antibody, and anti-AIDS virus antibody.
- an artificial blood vessel containing such a physiologically active substance as a biologically active substance there is an application such as an artificial blood vessel that also treats diseases such as diabetes and infectious disease.
- Examples of the gene used as a biologically active substance include a gene encoding the above-mentioned physiologically active substance, such as a gene encoding adenosine deaminase, a gene encoding an eighth blood coagulation factor, 9 Genes encoding blood coagulation factors, and the like.
- a gene encoding the above-mentioned physiologically active substance such as a gene encoding adenosine deaminase, a gene encoding an eighth blood coagulation factor, 9 Genes encoding blood coagulation factors, and the like.
- an artificial blood vessel containing a gene as a bioactive substance there is an application as an artificial blood vessel that also serves to treat diseases such as adenosine deaminase deficiency and hemophilia.
- a pharmaceutical compound synthesized or obtained in vitro can be used as a biologically active substance.
- examples of such pharmaceutical compounds include organic compounds, antibiotics produced by microorganisms existing in nature, and the like. Specific examples include penicillin, cyclophosphamide, actinomycin D, and 5-f / leuroushi / And pleomycin.
- An artificial blood vessel containing such a pharmaceutical compound as a biologically active substance has a use as an artificial blood vessel which also serves as an infectious disease, an anticancer treatment and the like.
- the gel solution contains at least smooth muscle cells and blast cells from the viewpoint of securing the mechanical strength after the artificial blood vessel transplantation.
- undifferentiated cells are included.
- the density of the bioactive substance to be mixed with the gel solution is preferably 1 ⁇ 10 4 eell Zml to l ⁇ 10 9 cel 1 Zm1, and 1 ⁇ 10 0 and still more preferably 6 a ce 1 1 / m 1 ⁇ 1 X 1 0 7 ce 1 1 Zm 1.
- the gel solution is a solution obtained by gelling a solution that gels due to changes in temperature, H, salt concentration, enzymatic reaction, etc., and is not particularly limited as long as it has no toxicity or carcinogenicity. it can.
- the gelling agent corresponding to the temperature change include collagen, acrylamide resin, and agarose.
- collagen that can be gelled in response to a pH change can be exemplified.
- Alginic acid or the like can be used as a gel that responds to changes in salt concentration.
- fibrin and the like can be mentioned as those that gel in response to the enzymatic reaction, and fibrinogen and the like can be mentioned as the enzyme to be gelled.
- a gel solution containing a biologically active substance is taken into the pores of the porous artificial blood vessel base material.
- the bioactive substance-containing gel solution preferably occupies 50% or more of all pores of the porous artificial vascular base material, and 90%, from the viewpoint of preventing blood leakage and securing a scaffold for vascular endothelial cells. It is more preferable to account for the above.
- an endothelial cell layer may be formed on the lumen surface of the porous artificial blood vessel base material from the viewpoint of improving antithrombotic properties.
- the porous artificial blood vessel base material is strengthened by a strengthening member made of a biodegradable material or a non-biodegradable material. You may.
- the reinforcing member may be formed on the outer peripheral surface and / or the inner peripheral surface of the porous artificial blood vessel base material, or may be incorporated inside the porous artificial blood vessel base material.
- the reinforcing member formed on the outer peripheral surface of the porous artificial blood vessel base material has a substantially same inner diameter as the outer diameter of the porous artificial blood vessel base material, and has a cross section concentric with the base material.
- a coated tubular member can be mentioned.
- the capturing member formed on the inner peripheral surface of the porous artificial blood vessel base material has an outer diameter substantially equal to the inner diameter of the porous artificial blood vessel base material, and has a cross section concentric with the base material. And a cylindrical member covered with a base material.
- a material formed by weaving a fibrous biodegradable material or a non-biodegradable material into a mesh shape can be used.
- the capturing member can also be incorporated into the porous artificial blood vessel base material.
- the biodegradation Examples of the porous material and the non-biodegradable material include those described above as the material for the porous artificial blood vessel base material.
- a biologically active substance is mixed with a solution that gels in response to any of a temperature change, a pH change, a salt concentration change, and an enzyme reaction change to prepare a biologically active substance-containing solution.
- the biologically active substance to be mixed can be appropriately determined according to the use of the artificial blood vessel, and includes the substances described above.
- the density of the biological agent to be mixed in the solution to gel, if the biological agent is a cell is a 1 X 1 0 4 ce 1 l Zm l ⁇ 1 X 1 0 9 ce 1 1 Zm 1 It is more preferably 1 ⁇ 10 6 ce 1 l / ml to 1 ⁇ 10 7 ce 11 Zm 1.
- the porous artificial vascular base material prepared in advance is impregnated with the solution containing the biologically active substance prepared as described above, and the biologically active substance is introduced into the pores of the substrate under normal pressure conditions, preferably under negative pressure conditions. Allow the containing solution to be incorporated.
- porous artificial blood vessel base material The material and manufacturing method of the porous artificial blood vessel base material are as described above. Further, the porous artificial blood vessel base material may be captured by a capturing member. The reinforcing member and the reinforcing method are as described above.
- the method for impregnating the porous artificial vascular base material into the biologically active substance-containing solution is as follows. There are several methods. In order to incorporate the biologically active substance into the substrate, the biologically active substance is impregnated until the biologically active substance is sufficiently incorporated into the pores of the porous artificial blood vessel substrate. For example, it is preferable that the bioactive substance-containing solution is impregnated with the porous artificial blood vessel substrate, and is left standing for 10 to 60 minutes, more preferably 30 to 60 minutes.
- the pressure at the time of addition may be normal pressure, but from the viewpoint of efficiently incorporating the bioactive substance into the pores of the substrate, a pressure lower than the atmospheric pressure is preferable. This pressure is appropriately determined in consideration of the materials to be used, the pressure resistance of the equipment, the possibility of retaining the activity of the biologically active substance to be used, and the like.
- the biologically active substance-containing solution taken into the pores of the porous artificial blood vessel substrate is gelled.
- the gelling conditions are set appropriately according to the solution to be used. Gelled In this case, from the viewpoint of forming a smooth lumen surface, it is preferable to further allow the mixture to stand for 10 minutes to 120 minutes under gelation conditions, and more preferably to allow the mixture to stand still for 30 minutes to 60 minutes. .
- an endothelial cell layer can be formed on the luminal surface of the porous artificial blood vessel base material.
- the endothelial cell layer is easily formed by pouring a culture solution containing endothelial cells into the lumen of a porous artificial blood vessel substrate holding a solution containing a bioactive substance that has undergone genoleration in the pores and rotating the culture. be able to.
- the number of rotations during the culture of endothelial cells is preferably from 0.5 rpm to 100 rpm, more preferably from 5 rpm to 10 rpm.
- the culture time is preferably from 10 minutes to 24 hours, and more preferably from 20 minutes to 60 minutes.
- the bioactive substance is contained at high density in the hole of a cylindrical porous artificial blood vessel base material, blood leakage does not occur, the lumen surface is almost smooth, and the porous artificial blood vessel Since it has a base material, an artificial blood vessel having excellent mechanical properties can be provided. Further, according to the present invention, a biologically active substance can be efficiently and rapidly incorporated into an artificial blood vessel in a short time.
- a porous artificial blood vessel substrate (hereinafter, referred to as “PLLA substrate”) composed of polylactic acid with a length of about 2 mm and a length of about 2 Omm was prepared.
- a solution was prepared by mixing human normal aortic vascular smooth muscle cells at a concentration of 5 ⁇ 10 6 cells / ml with a 0.39% collagen solution.
- the PLLA substrate prepared in the reference example was placed in a glass tube and immersed in 1.4 ml of the above-mentioned collagen solution containing human normal aortic vascular smooth muscle cells, and this was pumped with a hydraulic pump (ULVAC, G The pressure was reduced according to -5), and the mixture was allowed to stand under negative pressure for 30 minutes.
- the tube is moved to an incubator at 37 ° C and left standing for 60 minutes to gel the collagen solution in the PLLA substrate. Then, an artificial blood vessel was prepared.
- Human normal aortic vascular smooth muscle cells were mixed with a culture solution (Dulbecco's minimum essential medium (DMEM)) to prepare a cell-containing solution having a concentration of 5 ⁇ 10 6 cells / ml.
- DMEM Dulbecco's minimum essential medium
- the PLLA substrate prepared in Reference Example was placed in a glass tube, immersed in 1.4 ml of the above-described culture medium containing human normal aortic vascular smooth muscle cells, and this was immersed in a hydraulic pump ( , G-5) and allowed to stand under negative pressure for 30 minutes.
- a hydraulic pump , G-5
- the tube was moved to an incubator at 37 ° C and left standing for 60 minutes to produce an artificial blood vessel.
- Example 1 The numbers of human normal aortic vascular smooth muscle cells taken into the artificial blood vessels prepared in Example 1 and Comparative Example 1 were compared. For comparison, calculate the ratio (%) of the number of cells in the solution after immersing the PLLA substrate to the number of cells in the human normal aortic vascular smooth muscle cell solution before immersing the PLLA substrate. It was done by doing. The number of cells was determined by calculating the number of nuclei developed with 4,, 6-diamidino 2-phenylindole dihydrochloride (DAP I) using a fluorescence spectrophotometer. Since the immersion time is 30 minutes, smooth muscle cells do not proliferate during this time. Table 1 below shows the percentage of cells taken up. Example 1 Comparative Example 1 Percentage of cells taken up (%) 100% 18%
- Example 1 takes up cells extremely efficiently as compared to the artificial blood vessel prepared in Comparative Example 1.
- FIG. Fig. 2 shows an EM photograph
- Fig. 3 shows an SEM photograph of the state of the lumen surface of the PLLA substrate prepared in Reference Example for reference. From FIGS. 1 and 2, the luminal surface of the artificial blood vessel of Comparative Example 1 is smooth without any holes, while the luminal surface of the artificial blood vessel of Comparative Example 1 is still large. I understand.
- each artificial blood vessel was further cultured for one day, and then a cross-sectional section (8 ⁇ thick) of each artificial blood vessel was prepared.
- the nucleus of human normal aortic vascular smooth muscle cells was Hoechst ( Hextone earth) (100 ⁇ g / m1).
- FIG. 4 shows a fluorescence photograph of a cross section of the artificial blood vessel produced in Example 1
- FIG. 5 shows a fluorescence photograph of a cross section of the artificial blood vessel produced in Comparative Example 1.
- the dotted line in the figure indicates the lumen surface. 4 and 5 that the artificial blood vessel prepared in Example 1 'incorporates cells at a higher density than the artificial blood vessel prepared in Comparative Example 1. '
- a culture solution containing normal human umbilical vein vascular endothelial cells at a concentration of 5.0 ⁇ 10 6 cells / ml was prepared in a volume of 1 ml, and poured into the lumen of the artificial blood vessel prepared in Example 1.
- a rotary culture device Titech, RT-50
- 5111 to 10 ⁇ An endothelial cell layer was formed by culturing for 60 minutes while rotating at a rotating speed.
- Fig. 6 shows a transmission micrograph of the cross section of the artificial blood vessel
- Fig. 7 shows a fluorescence photograph of the same cross section.
- the arrow in FIG. 7 indicates the endothelial cell layer. 6 and 7 that the endothelial cell layer is continuously formed on the luminal surface of the artificial blood vessel prepared in Example 2.
- the present invention it is possible to smooth the minimum cavity surface in direct contact with blood, which is indispensable for an artificial blood vessel, in a short period of time, and to efficiently and efficiently produce a bioactive substance in a short time. Incorporation into blood vessels is possible.
- an artificial blood vessel which does not cause blood leakage, has excellent antithrombotic properties, has a substantially smooth lumen surface, and has excellent mechanical properties.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne un vaisseau artificiel, qui offre une biocompatibilité, une résistance mécanique et des propriétés antithrombotiques excellentes (entre autres caractéristiques), qui ne présente aucun risque de fuite de sang, et dont la réalisation est aisée. L'invention concerne également un procédé relatif à la réalisation d'un vaisseau artificiel ne présentant aucun risque de fuite de sang et offrant d'excellentes propriétés antithrombotiques, qui a une surface interne presque lisse et qui possède des propriétés mécaniques favorables. On peut réaliser un tel vaisseau en peu de temps, selon les étapes suivantes: immersion d'une substance biologiquement active dans une solution capable de se gélifier, pour donner une solution renfermant cette substance biologiquement active; incorporation de la solution renfermant la substance biologiquement active en question dans les pores d'un matériau de base poreux en forme de tube, utilisé pour la réalisation du vaisseau artificiel; puis gélification de la solution renfermant ladite substance biologiquement active, précédemment incorporée aux pores du matériau de base susmentionné.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001326426A JP2003126125A (ja) | 2001-10-24 | 2001-10-24 | 人工血管及びその製造方法 |
JP2001-326426 | 2001-10-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003034945A1 true WO2003034945A1 (fr) | 2003-05-01 |
Family
ID=19142812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/010986 WO2003034945A1 (fr) | 2001-10-24 | 2002-10-23 | Vaisseau artificiel et procede de realisation |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2003126125A (fr) |
WO (1) | WO2003034945A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007501676A (ja) * | 2003-05-07 | 2007-02-01 | アリーヴァ メディカル インコーポレイテッド | 栄養分および老廃物の交換を回復することによる腰痛の治療 |
CN116808279A (zh) * | 2023-08-25 | 2023-09-29 | 北京国械堂科技发展有限责任公司 | 一种亲水性复合胶原蛋白海绵及其制备方法 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004087012A1 (fr) | 2003-03-31 | 2004-10-14 | Teijin Limited | Composite forme d'un substrat de support et de collagene, procede de production du substrat de support et du composite |
JP2005034239A (ja) * | 2003-07-16 | 2005-02-10 | Gunze Ltd | 人工血管用基材 |
WO2005077432A2 (fr) * | 2004-02-09 | 2005-08-25 | Cook Incorporated | Prothese coulee bioremodelable |
US20060149363A1 (en) * | 2005-01-06 | 2006-07-06 | Scimed Life Systems, Inc. | Optimally expanded, collagen sealed ePTFE graft with improved tissue ingrowth |
JP2007307300A (ja) * | 2006-05-22 | 2007-11-29 | Hokkaido Univ | 人工血管用材料 |
KR101234276B1 (ko) | 2011-07-27 | 2013-02-18 | 서울대학교산학협력단 | 생체 외 혈관 생성 장치 및 이를 이용한 혈관 생성 방법 |
US11439731B2 (en) | 2016-09-14 | 2022-09-13 | Revotek Co., Ltd. | Artificial tissue progenitor and method for preparing the same |
CN109880795A (zh) * | 2016-09-14 | 2019-06-14 | 四川蓝光英诺生物科技股份有限公司 | 人工组织前体及制备其的方法 |
Citations (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3272204A (en) * | 1965-09-22 | 1966-09-13 | Ethicon Inc | Absorbable collagen prosthetic implant with non-absorbable reinforcing strands |
US4167045A (en) * | 1977-08-26 | 1979-09-11 | Interface Biomedical Laboratories Corp. | Cardiac and vascular prostheses |
US4321711A (en) * | 1978-10-18 | 1982-03-30 | Sumitomo Electric Industries, Ltd. | Vascular prosthesis |
US4546500A (en) * | 1981-05-08 | 1985-10-15 | Massachusetts Institute Of Technology | Fabrication of living blood vessels and glandular tissues |
US4804381A (en) * | 1986-06-02 | 1989-02-14 | Sulzer Brothers Limited | Artificial vessel |
US4911713A (en) * | 1986-03-26 | 1990-03-27 | Sauvage Lester R | Method of making vascular prosthesis by perfusion |
US4960423A (en) * | 1982-11-17 | 1990-10-02 | Smith Donald W | Method of enhancing the attachment of endothelial cells on a matrix and vascular prosthesis with enhanced anti-thrombogenic characteristics |
US5037377A (en) * | 1984-11-28 | 1991-08-06 | Medtronic, Inc. | Means for improving biocompatibility of implants, particularly of vascular grafts |
US5037378A (en) * | 1988-10-07 | 1991-08-06 | Sulzer Brothers Limited | Process for coating a flexible tubular prosthesis with living cells |
US5120833A (en) * | 1991-03-15 | 1992-06-09 | Alexander Kaplan | Method of producing grafts |
US5131907A (en) * | 1986-04-04 | 1992-07-21 | Thomas Jefferson University | Method of treating a synthetic naturally occurring surface with a collagen laminate to support microvascular endothelial cell growth, and the surface itself |
US5171261A (en) * | 1989-04-17 | 1992-12-15 | Koken Co., Ltd. | Vascular prosthesis, manufacturing method of the same, and substrate for vascular prothesis |
US5298255A (en) * | 1988-10-28 | 1994-03-29 | Terumo Kabushiki Kaisha | Antithrombic medical material, artificial internal organ, and method for production of antithrombic medical material |
WO1994022505A1 (fr) * | 1993-03-29 | 1994-10-13 | National Heart Research Fund | Equivalents tissulaires |
US5376118A (en) * | 1989-05-10 | 1994-12-27 | United States Surgical Corporation | Support material for cell impregnation |
US5415619A (en) * | 1989-12-13 | 1995-05-16 | Korea Research Institute Of Chemical Tech. | Method of manufacturing a vascular graft impregnated with polysaccharide derivatives |
US5470731A (en) * | 1992-05-29 | 1995-11-28 | The Regents Of The University Of California | Coated transplant and method for making same |
WO1996040175A1 (fr) * | 1995-06-07 | 1996-12-19 | Advanced Tissue Sciences, Inc. | Systeme de culture tridimensionnel base sur les cellules du stroma et destine a la formation de tubes, de tendons, de ligaments et de structures correctives |
WO1997000275A2 (fr) * | 1995-06-16 | 1997-01-03 | Gel Sciences, Inc. | Reticulats polymeriques sensibles a des changements intervenus dans des stimulus environnementaux et leurs procedes d'utilisation |
US5628786A (en) * | 1995-05-12 | 1997-05-13 | Impra, Inc. | Radially expandable vascular graft with resistance to longitudinal compression and method of making same |
US5716660A (en) * | 1994-08-12 | 1998-02-10 | Meadox Medicals, Inc. | Tubular polytetrafluoroethylene implantable prostheses |
US5718723A (en) * | 1994-03-15 | 1998-02-17 | Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) | Artificial blood vessel and process for producing the same |
WO1998010804A1 (fr) * | 1996-09-13 | 1998-03-19 | Meadox Medicals, Inc. | Materiaux d'etancheite a bioresorption ameliores pour greffons vasculaires poreux |
WO1998040111A1 (fr) * | 1997-03-07 | 1998-09-17 | University College London | Implant de tissus |
WO1998043686A1 (fr) * | 1997-04-03 | 1998-10-08 | California Institute Of Technology | Modification enzymatique de la fibrine destinee au genie tissulaire |
WO1999047188A1 (fr) * | 1998-03-17 | 1999-09-23 | Tissue Engineering, Inc. | Treillis biopolymere destine a etre utilise pour reparer et reconstruire des tissus |
US5986168A (en) * | 1995-04-25 | 1999-11-16 | Nicem, Ltd. | Prosthesis containing bioabsorbable materials insolubilized without chemical reagents and method of making the same |
US6057137A (en) * | 1994-10-06 | 2000-05-02 | Regents Of The University Of Minnesota | Tissue-equivalent rods containing aligned collagen fibrils and schwann cells |
WO2001010421A1 (fr) * | 1999-08-06 | 2001-02-15 | Board Of Regents, The University Of Texas System | Medicament liberant un implant de fibre biodegradable |
WO2001032382A1 (fr) * | 1999-11-03 | 2001-05-10 | Scimed Life Systems, Inc. | Procede d'impregnation d'une matiere poreuse avec une composition reticulable |
US6306424B1 (en) * | 1999-06-30 | 2001-10-23 | Ethicon, Inc. | Foam composite for the repair or regeneration of tissue |
-
2001
- 2001-10-24 JP JP2001326426A patent/JP2003126125A/ja active Pending
-
2002
- 2002-10-23 WO PCT/JP2002/010986 patent/WO2003034945A1/fr active Application Filing
Patent Citations (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3272204A (en) * | 1965-09-22 | 1966-09-13 | Ethicon Inc | Absorbable collagen prosthetic implant with non-absorbable reinforcing strands |
US4167045A (en) * | 1977-08-26 | 1979-09-11 | Interface Biomedical Laboratories Corp. | Cardiac and vascular prostheses |
US4321711A (en) * | 1978-10-18 | 1982-03-30 | Sumitomo Electric Industries, Ltd. | Vascular prosthesis |
US4546500A (en) * | 1981-05-08 | 1985-10-15 | Massachusetts Institute Of Technology | Fabrication of living blood vessels and glandular tissues |
US4960423A (en) * | 1982-11-17 | 1990-10-02 | Smith Donald W | Method of enhancing the attachment of endothelial cells on a matrix and vascular prosthesis with enhanced anti-thrombogenic characteristics |
US5037377A (en) * | 1984-11-28 | 1991-08-06 | Medtronic, Inc. | Means for improving biocompatibility of implants, particularly of vascular grafts |
US4911713A (en) * | 1986-03-26 | 1990-03-27 | Sauvage Lester R | Method of making vascular prosthesis by perfusion |
US5131907A (en) * | 1986-04-04 | 1992-07-21 | Thomas Jefferson University | Method of treating a synthetic naturally occurring surface with a collagen laminate to support microvascular endothelial cell growth, and the surface itself |
US4804381A (en) * | 1986-06-02 | 1989-02-14 | Sulzer Brothers Limited | Artificial vessel |
US5037378A (en) * | 1988-10-07 | 1991-08-06 | Sulzer Brothers Limited | Process for coating a flexible tubular prosthesis with living cells |
US5298255A (en) * | 1988-10-28 | 1994-03-29 | Terumo Kabushiki Kaisha | Antithrombic medical material, artificial internal organ, and method for production of antithrombic medical material |
US5171261A (en) * | 1989-04-17 | 1992-12-15 | Koken Co., Ltd. | Vascular prosthesis, manufacturing method of the same, and substrate for vascular prothesis |
US5376118A (en) * | 1989-05-10 | 1994-12-27 | United States Surgical Corporation | Support material for cell impregnation |
US5415619A (en) * | 1989-12-13 | 1995-05-16 | Korea Research Institute Of Chemical Tech. | Method of manufacturing a vascular graft impregnated with polysaccharide derivatives |
US5120833A (en) * | 1991-03-15 | 1992-06-09 | Alexander Kaplan | Method of producing grafts |
US5470731A (en) * | 1992-05-29 | 1995-11-28 | The Regents Of The University Of California | Coated transplant and method for making same |
WO1994022505A1 (fr) * | 1993-03-29 | 1994-10-13 | National Heart Research Fund | Equivalents tissulaires |
US5718723A (en) * | 1994-03-15 | 1998-02-17 | Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) | Artificial blood vessel and process for producing the same |
US5716660A (en) * | 1994-08-12 | 1998-02-10 | Meadox Medicals, Inc. | Tubular polytetrafluoroethylene implantable prostheses |
US6057137A (en) * | 1994-10-06 | 2000-05-02 | Regents Of The University Of Minnesota | Tissue-equivalent rods containing aligned collagen fibrils and schwann cells |
US5986168A (en) * | 1995-04-25 | 1999-11-16 | Nicem, Ltd. | Prosthesis containing bioabsorbable materials insolubilized without chemical reagents and method of making the same |
US5628786A (en) * | 1995-05-12 | 1997-05-13 | Impra, Inc. | Radially expandable vascular graft with resistance to longitudinal compression and method of making same |
WO1996040175A1 (fr) * | 1995-06-07 | 1996-12-19 | Advanced Tissue Sciences, Inc. | Systeme de culture tridimensionnel base sur les cellules du stroma et destine a la formation de tubes, de tendons, de ligaments et de structures correctives |
WO1997000275A2 (fr) * | 1995-06-16 | 1997-01-03 | Gel Sciences, Inc. | Reticulats polymeriques sensibles a des changements intervenus dans des stimulus environnementaux et leurs procedes d'utilisation |
WO1998010804A1 (fr) * | 1996-09-13 | 1998-03-19 | Meadox Medicals, Inc. | Materiaux d'etancheite a bioresorption ameliores pour greffons vasculaires poreux |
WO1998040111A1 (fr) * | 1997-03-07 | 1998-09-17 | University College London | Implant de tissus |
WO1998043686A1 (fr) * | 1997-04-03 | 1998-10-08 | California Institute Of Technology | Modification enzymatique de la fibrine destinee au genie tissulaire |
WO1999047188A1 (fr) * | 1998-03-17 | 1999-09-23 | Tissue Engineering, Inc. | Treillis biopolymere destine a etre utilise pour reparer et reconstruire des tissus |
US6306424B1 (en) * | 1999-06-30 | 2001-10-23 | Ethicon, Inc. | Foam composite for the repair or regeneration of tissue |
WO2001010421A1 (fr) * | 1999-08-06 | 2001-02-15 | Board Of Regents, The University Of Texas System | Medicament liberant un implant de fibre biodegradable |
WO2001032382A1 (fr) * | 1999-11-03 | 2001-05-10 | Scimed Life Systems, Inc. | Procede d'impregnation d'une matiere poreuse avec une composition reticulable |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007501676A (ja) * | 2003-05-07 | 2007-02-01 | アリーヴァ メディカル インコーポレイテッド | 栄養分および老廃物の交換を回復することによる腰痛の治療 |
CN116808279A (zh) * | 2023-08-25 | 2023-09-29 | 北京国械堂科技发展有限责任公司 | 一种亲水性复合胶原蛋白海绵及其制备方法 |
CN116808279B (zh) * | 2023-08-25 | 2023-11-21 | 北京国械堂科技发展有限责任公司 | 一种亲水性复合胶原蛋白海绵及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2003126125A (ja) | 2003-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Khandan et al. | Hydrogels: Types, structure, properties, and applications | |
Angelova et al. | Rationalizing the design of polymeric biomaterials | |
Thein-Han et al. | Chitosan as scaffold matrix for tissue engineering | |
Kundu et al. | Biomaterials for biofabrication of 3D tissue scaffolds | |
Choi et al. | Biodegradable porous beads and their potential applications in regenerative medicine | |
Lutzweiler et al. | Modulation of cellular colonization of porous polyurethane scaffolds via the control of pore interconnection size and nanoscale surface modifications | |
CN104725660A (zh) | 制备用于组织工程、细胞培养和细胞传递的多孔支架的方法 | |
EP2793962B1 (fr) | Procédé de modification de la morphologie de surface d'un dispositif médical | |
CN105688274B (zh) | 一种聚己内酯/明胶电纺复合支架的制备工艺 | |
JP6118905B2 (ja) | 心臓修復パッチの新しいスキャフォールド | |
JPH04501080A (ja) | 重合マトリックス上の大容量の細胞の移植方法 | |
JP5507566B2 (ja) | 血管壁臨時骨格(補助材)用の生分解性ブレンド | |
US20040062809A1 (en) | Biocompatible polymer with a three-dimensional structure with communicating cells, a process for its preparation, and application in medicine and in surgery | |
CN101264341A (zh) | 三维多孔组织工程支架材料、其制备及应用 | |
Tian et al. | Fabrication of nanocomposite bioelastomer porous scaffold based on chitin nanocrystal supported emulsion-freeze-casting | |
US20050165475A1 (en) | Hybrid grafts including biodegradable polymer supporting layer and manufacturing process thereof | |
JP4002299B2 (ja) | 組織処理用の改善されたヒドロゲル | |
Tamay et al. | Bioinks—materials used in printing cells in designed 3D forms | |
WO2003034945A1 (fr) | Vaisseau artificiel et procede de realisation | |
US8431623B2 (en) | Process for forming a porous PVA scaffold using a pore-forming agent | |
JP2017196150A (ja) | 移植用デバイス及びバイオ人工臓器 | |
CN104708736A (zh) | 一种改性聚乙烯醇水凝胶材料及专用模具、制备方法和应用 | |
JP3831402B2 (ja) | 生分解性樹脂及びリン酸カルシウムを含む再生医療用材料及びその製造方法 | |
Higuera et al. | PEOT/PBT polymeric pastes to fabricate additive manufactured scaffolds for tissue engineering | |
Mamat et al. | Hierarchical bioceramic scaffold for tissue engineering: A review |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase |